InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.460 -0.065 (-12.38%)+
Announcement
Release
20 Feb 2026 9:39AM
Price at Release
$0.525
Full Release
download
Summary
During the half-year ended 31 December 2025, Cambium Bio Limited made significant progress in its lead product, Elate Ocular®, moving towards Phase 3 clinical trials with regulatory approvals and strategic partnerships. The company established collaborations with Keke Medtech and Benta SAS, enhancing its market presence in dental applications and regions like Europe and the Middle East. Financially, while still operating at a loss, Cambium Bio improved its revenue and secured non-dilutive funding through the Australian R&D Tax Incentive. The company's stable board continues to focus on leveraging expertise to advance its clinical and commercial objectives.
Key Points
  • Cambium Bio Limited advanced its Elate Ocular® program toward Phase 3 trials during the half-year ended 31 December 2025.
  • The FDA confirmed satisfaction of CMC requirements, allowing patient dosing in Phase 3 trials for Elate Ocular®.
  • Strategic partnerships include agreements with Keke Medtech for dental applications and Benta SAS for European and Middle East rights.
  • Revenue from ordinary activities increased by 9% to $326,889 compared to the previous year.
  • The company reported a net loss of $1,456,000, showing a 16% improvement from the previous period.
  • The R&D Tax Incentive provides a 43.5% cash rebate on eligible expenditure, strengthening the company’s financial position.
  • Cambium Bio's Board maintains expertise in ophthalmology, clinical trials, and international business development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.